This may be the main reason why CD34_CAFs’ role in highly aggressive BC subtypes such as HER2 and TNBC is underestimated in its relationship with other clinic-pathologic parameters and stromal vascular and immune components. The gene discussed is ERBB2; the disease is breast cancer.